<DOC>
	<DOCNO>NCT00559481</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood laboratory patient cancer receive ketoconazole together dexamethasone hydrocortisone may help doctor learn drug use body . PURPOSE : This randomized clinical trial study ketoconazole , dexamethasone , hydrocortisone act body patient prostate cancer respond androgen-deprivation therapy .</brief_summary>
	<brief_title>Ketoconazole , Dexamethasone , Hydrocortisone Treating Patients With Prostate Cancer That Did Not Respond Androgen-Deprivation Therapy</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate pharmacokinetics oral dexamethasone without oral ketoconazole patient androgen-independent prostate cancer . - To compare pharmacokinetics oral hydrocortisone without oral ketoconazole patient . OUTLINE : Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral dexamethasone twice daily day 1-14 , oral ketoconazole 3 time daily day 2-14 30-42 , oral hydrocortisone twice daily day 29-42 . - Arm II : Patients receive oral hydrocortisone twice daily day 1-14 , oral ketoconazole 3 time daily day 2-14 30-42 , oral dexamethasone twice daily day 29-42 . In arm , patient may receive ketoconazole hydrocortisone standard salvage therapy study . In arm , patient undergo blood sample collection day 1 , 14 , 29 , 42 pharmacokinetic study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed diagnosis prostate cancer Must fail standard androgendeprivation therapy Evidence rise PSA PATIENT CHARACTERISTICS : ECOG performance status 02 Creatinine â‰¤ 2.0 mg/dL AST ALT &lt; 4 time upper limit normal Bilirubin &lt; 2.0 mg/dL No active congestive heart failure No allergy ketoconazole , dexamethasone , hydrocortisone , one component dexamethasone , hydrocortisone , ketoconazole No active infection No uncontrolled glaucoma No active peptic ulcer disease No uncontrolled diabetes mellitus Fertile patient must use effective contraception 3 month completion study therapy PRIOR CONCURRENT THERAPY : More 2 week since prior concurrent drug know interact study treatment</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>recurrent prostate cancer</keyword>
</DOC>